Northern Trust Corp Caladrius Biosciences, Inc. Transaction History

Northern Trust Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$0.83 - $1.22 $1,207 - $1,775	-1,455 Reduced 1.67%	85,855 $72,000
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.57 $1,673 - $2,284	1,455 Added 1.69%	87,310 $107,000
Q1 2021 May 12, 2021	BUY	$1.44 - $2.89 $98,822 - $198,332	68,627 Added 398.35%	85,855 $166,000
Q4 2020 Feb 11, 2021	BUY	$1.39 - $1.87 $23,946 - $32,216	17,228 New	17,228 $25,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.